Back to Search
Start Over
B-cell–targeted therapies in relapsing forms of MS
- Source :
- Neurology® Neuroimmunology & Neuroinflammation
- Publication Year :
- 2017
- Publisher :
- Lippincott Williams & Wilkins, 2017.
-
Abstract
- In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-to-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell–directed therapeutic strategies.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
medicine.drug_class
MEDLINE
Phases of clinical research
Monoclonal antibody
03 medical and health sciences
0302 clinical medicine
Text mining
Internal medicine
Medicine
Adverse effect
B cell
Views & Reviews
biology
business.industry
3. Good health
Clinical trial
030104 developmental biology
medicine.anatomical_structure
Neurology
biology.protein
Neurology (clinical)
Antibody
business
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 23327812
- Volume :
- 4
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Neurology® Neuroimmunology & Neuroinflammation
- Accession number :
- edsair.doi.dedup.....793285d8f4e33d62a1b4f3674dfd98dd